Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Suicidality in Bipolar Depression (DEEPP)
NCT05177146Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- May 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ketamine in bipolar disorder (BD), sponsored by Center for Addiction and Mental Health. Primary endpoints: Intracortical Facilitation at 1 month and Short-Interval Cortical Inhibition at 1 month. Started May 2022; status: completed.
02
Drugs
ketamine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT05177146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177146.